Vedolizumab-Induced De Novo Extraintestinal Manifestations

  Abstract: Background: Vedolizumab is an α4β7 integrin antagonist with gut-specific effects on lymphocyte and monocyte trafficking. Although the treatment is beneficial for inflammatory bowel disease (IBD), […]